Additionally, LASS2 knockdown enhanced resistance to cisplatin and carboplatin, but not to other commonly used chemotherapy agents in bladder cancer, such as gemcitabine, methotrexate, and vinblastine, indicating a specific effect of LASS2 on platinum (Fig. 1I, Additional file 2: Fig. S4C). The gene discussed is CERS2; the disease is urinary bladder carcinoma.